Your search found 3 Results
[Unpublished] .  p.Since HIV was first identified as the cause of AIDS, a number of research efforts have been concentrated on identifying and developing antiretroviral compounds to suppress its replication. Over the years, these researches have noted that sustained suppression of HIV replication is achievable through the use of triple antiretroviral therapy. However, reservoirs of HIV in patients under treatment still remain and there are studies which indicate that the virus may not be latent but instead replicating at a slow rate. In this perspective, researchers are seeking alternatives to triple therapy, and looking at quadruple therapy and new classes of drugs. In the meantime, it is generally accepted that combination therapy represents the best treatment option available. Hence, the long-term sustainability and safety of antiretrovirals is emphasized. Given the gross imbalance in availability and access to antiretrovirals between the industrialized and developing countries, a set of guiding principles has been drawn up by the WHO and Joint UN Programme on HIV/AIDS (UNAIDS). Moreover, UNAIDS efforts in improving access to antiretrovirals are being acknowledged, particularly in developing countries.
Death watch, Part 6. A turning point that left millions behind. Drug discounts benefit few while protecting pharmaceutical companies' profits.
WASHINGTON POST. 2000 Dec 28; A1.The deal between 5 major pharmaceutical companies and 5 international agencies announced on May 11, 2000 to provide affordable AIDS medicines in poor countries was considered a turning point in the world’s response to the poorest AIDS sufferers. It is noted that doubts and disputes rived the potential partners, and each side tried in some measure to subvert the other’s goals. The agencies had an unspoken aim to drive prices of patented AIDS drugs down to the level of generics, and to make those prices available as widely as possible. Meanwhile, the drug companies are negotiating variable prices in strict confidence and neither the companies nor their partners have committed in practical terms to bring treatment to significant numbers of the dying. The drug discounts proposed and implemented have benefited only a few while protecting pharmaceutical companies’ profits.
Bulletin of the World Health Organization. 2000; 78(12):1454-5.Malaria is unarguably a disease that can still be both prevented and treated effectively. It is also a large and growing burden of disease in the world that is grossly inconsistent with modern health standards, and it receives far too little attention. The Roll Back Malaria (RBM) movement was established as a response to the situation. The RBM goal is to continue developing a reserve of effective technologies for preventing and treating malaria. This article discusses some of the challenges in the task of reducing incidence of malaria. Five main concerns expressed at a WHO round table discussion were: massive cost, resistance to drugs and insecticides, inadequate local capacity, the false impression that there has been a lack of new initiatives, and the horizontal approach. Overall, it is emphasized that such difficulties can be tackled by applying science, human and financial resources, and effective organization. Most important, though, is the recognition of the need to oppose the suffering and deprivation caused by malaria.